Pharma giant Bristol-Myers Squibb just made another big bet on cancer immunotherapy – Business Insider
Business Insider |
Pharma giant Bristol-Myers Squibb just made another big bet on cancer immunotherapy
Business Insider Bristol-Myers has two drugs, Opdivo and Yervoy, that are a part of a new class of cancer treatments called cancer immunotherapy that harness the body’s immune system to go after cancer. Unlike chemotherapy, which involves administering powerful drugs … IFM Gets $300M Bristol Buyout, Plans Second Strike With New SpinoutXconomy |
|
Behind The Hype, Crispr Is A Story Of Slow Progress And Acrimony
Seeking Alpha Some people reading this morning’s mainstream press headlines about a Nature paper describing the correction of a germline mutation using Crispr (NASDAQ:CRSP) might be excused for thinking that we are entering a Gattaca-like world of designer babies. Trading Spotlight on Crispr Therapeutics AG (CRSP) SharesBenton Bulletin Marathon Asset Management Llp Boosted Compania De Minas Buenaventura (BVN) Holding; Crispr Therapeutics AG …FlintDaily.com |
|
Boy undergoes stem cell therapy for autism
Times of India Udaipur: A seven-year-old boy, resident of Udaipur, underwent stem cell therapy in a Mumbai’s private hospital for treatment of Attention Deficit Hyperactive Disorder (Autism). “Stem cell therapy is emerging as one of the newer treatment options for … |
NEPA Scene (blog) |
Northeast PA Innovation Conference in Scranton covers latest bioscience and health tech Aug. 10-11
NEPA Scene (blog) Terzaghi is presenting “Using Bioinformatics and Synthetic Biology for Bioremediation of Atrazine and to Develop Novel Treatments for Kidney Stones.” His research applies bioinformatics to identify genes which can be used to develop plants that can … |